AJNA BioSciences, a Littleton company, is developing a psilocybin mushroom-based drug as a legal alternative to traditional antidepressants. Having obtained a federal license, the firm aims to create a standardized psilocybin product for FDA approval. However, obstacles exist due to the unique nature of botanic drugs in the modern regulation system. Clinical trials are underway, with optimism for FDA approval.
Read the full story here
Written by: Christine Ricciardi
Published on January 14, 2024 at 10:07PM
Source: News – Hartford Courant (opens in new tab)